Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.

Y Tomita,R J Motzer,T K Choueiri, B I Rini,H Miyake,M Oya,L Albiges,M Aizawa,Y Umeyama,J Wang,A di Pietro,M Schmidinger

ESMO open（2023）

引用 0|浏览6

暂无评分

摘要

In post hoc analyses, first-line treatment with avelumab + axitinib was generally associated with efficacy benefits versus treatment with sunitinib in patients with advanced renal cell carcinoma across subgroups defined by different numbers of IMDC risk factors or target tumor sites.

查看译文

关键词

avelumab,axitinib,risk factor,tumor site,renal cell carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要